Shareholders at Episurf Medical approved a name change to Episurf AB and authorized the issuance of up to 1.3 billion warrants, paving the way for potential share dilution to fund working capital and acquisitions.
The extra general meeting on 12 November 2026 approved charter changes allowing the board to issue new shares, convertibles and warrants under the mandate from the AGM of 25 May 2026 to raise working capital and finance acquisitions, plus warrant programs totalling up to 1 300 000 000 options for staff and the board. This paves the way for new share issuance and potential dilution, which typically weighs on the share price. The approved name change to Episurf AB is cosmetic and does not affect value.
Episurf Medical AB held an extraordinary general meeting on 12 November 2026, approving a name change to Episurf AB and charter amendments to facilitate future capital raises. Shareholders also authorized two long-term warrant programs, issuing up to 1 000 000 000 options for employees and 300 000 000 options for board members to support the company's growth strategy.
On 12 November 2026 it approved a name change to Episurf AB, charter changes allowing new share issues to raise working capital and finance acquisitions, and two long-term warrant programs: up to 1 000 000 000 options for employees and up to 300 000 000 options for board members.
The approvals make it easier for the board to issue new shares or convertibles, which can dilute existing shareholders' ownership; the market often reacts negatively to dilution risk, though no specific issue amount was decided yet.